NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover.
How this guideline was developed
NICE commissioned the National Clinical Guideline Centre to develop this guideline. The Centre established a Guideline Development Group (see section 4), which reviewed the evidence and developed the recommendations.
The methods and processes for developing NICE clinical guidelines are described in the guidelines manual.
Details are correct at the time of publication of the guideline (June 2015). Further information is available on the NICE website.
Chronic kidney disease (2014) NICE guideline CG182
Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (2014) NICE technology appraisal guidance 323
Acute kidney injury (2013) NICE guideline CG169
Peritoneal dialysis (2011) NICE guideline CG125
Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (2002) NICE technology appraisal guidance 48
NICE is developing the following guidance: